Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B

Thrombosis and Haemostasis

Volumn 93, Issue 3, 2005, Pages 475-480

  Dargaud, Yesim ^a   Béguin, Suzette ^b   Lienhart, Anne ^a   Al Dieri, Raed ^b   Trzeciak, Christine ^a   Bordet, Jean Claude ^a   Hemker, H Coenraad ^b   Negrier, Claude ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Factor IX; Factor VIII; Haemophilia; Thrombin generation

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; THROMBIN;

ADULT; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISEASE SEVERITY; EX VIVO STUDY; FEMALE; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; MALE; PHENOTYPE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SURGICAL TECHNIQUE; THROMBIN TIME; TREATMENT PLANNING;

ADULT; BLOOD COAGULATION TESTS; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HEMORRHAGE; HUMANS; KINETICS; MIDDLE AGED; PHENOTYPE; THROMBIN;

EID: 15344343052     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-10-0706     Document Type: Article

References (23)

1. Mannucci PM, Tuddenham EG. The hemophilias - from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9.
2. Al Dieri R, Peyvandi F, Santagostino E, et al. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost 2002; 88: 576-82.
3. Chantarangkul V, Clerici M, Bressi C, et al. Thrombin generation assessed as endogenous thrombin potential in patients with hyper-or hypo-coagulability. Haematologica 2003; 88: 547-54.
4. Siegemund T, Petros S, Siegemund A, et al. Thrombin generation in severe haemophilia A and B: the endogenous thrombin potential in platelet-rich plasma. Thromb Haemost 2003; 90: 781-6.
5. Varadi K, Negrier C, Berntorp E, et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003; 1: 2374-80.
6. Hemker HC, Beguin S. Phenotyping the clotting system. Thomb Haemost 2000; 84: 747-51.
7. Hemker HC, Giesen P, AlDieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
8. Hope MJ, Bally MB, Webb G, et al. Production of large unilamellar vesicles by rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta 1985; 812: 55-65.
9. Hedegaard E, Jensen B. Nano-scale densitometric quantitation of phospholipids. J Chromatogr 1981; 225: 450-4.
10. Ghosh K, Shetty S, Mohanty D. Milder clinical presentation of hemophilia A with severe deficiency of factor VIII as measured by one-stage assay. Haemophilia 2001; 7: 9-12.
11. Nowak-Gottl U, Escuriola C, Kurnik K, et al. Haemophilia and thrombophilia. Hamostaseologie 2003; 23: 36-40.
12. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterized by poor anticoagulant response to activated protein C : prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
13. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
14. Nichols WC, Amano K, Cacheris PM et al. Moderation of hemophilia A phenotype by the factor V R506Q mutation. Blood 1996; 88: 1183-7.
15. Lee DH, Walker IR, Teitel J, et al. Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia A. Thromb Haemost 2000; 83: 387-91.
16. Curvers J, Thomassen MC, Rimmer J, et al. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. Thromb Haemost 2002; 88: 5-11
17. Wielders S, Mukherjee M, Michiels J, et al. The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability. Thromb Haemost 1997; 77: 629-36.
18. Tans G, van Hylckama Vlieg A, Thomassen MC, et al. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 2003; 122: 465-70.
19. Dacosta A, Mismetti P, Tardy B, et al. Thrombosis and carbamazepine: hazard or causality? Therapie 1994; 49: 355-6.
20. Simon JP, Hanesse B, Trechot P, et al. Repeated thromboses during treatment with carbamazepine. Therapie 1993; 48: 491.
21. Nakaso K, Shimoda M, Yasui K, et al. A case of superior sagittal sinus thrombosis following long-term medication with carbamazepine. Rinsho Shinkeigaku. 2000; 40: 617-20.
22. 2+levels. J Psychiatry Neurosci 2003; 28: 115-25.
23. Giansily-Blaizot M, Al Dieri R, Schved JF. Thrombin generation measurement in factor VII-depleted plasmas compared to inherited factor VII-deficient plasmas. Pathophysiol Haemost Thromb 2003; 33: 36-42.